Checkpoint blockade and microsatellite instability

Patent metadata

Field	Value
Publication number	US-11649287-B2
Application number	US-202117465096-A
Country	US
Kind code	B2
Filing date	Sep 2, 2021
Priority date	Nov 13, 2014
Publication date	May 16, 2023
Grant date	May 16, 2023

Abstract

Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

First claim

We claim:

1. A method for treating colorectal cancer in a human patient, the method comprising:
in response to determining that the colorectal cancer is microsatellite instability high or DNA mismatch repair deficient, treating a human patient having colorectal cancer that is microsatellite instability high or DNA mismatch repair deficient with a therapeutically effective amount of pembrolizumab, wherein a biological sample from the patient had previously been tested to determine whether the colorectal cancer is microsatellite instability high or DNA mismatch repair deficient.

2. The method of claim 1 , wherein the biological sample is tumor tissue from the patient.

3. The method of claim 1 , wherein the biological sample is a body fluid from the patient.

4. The method of claim 1 , wherein the colorectal cancer is microsatellite instability high.

5. The method of claim 1 , wherein the colorectal cancer is DNA mismatch repair deficient.

6. The method of claim 1 , wherein the colorectal cancer is metastatic colorectal cancer.

7. The method of claim 1 , wherein the patient had received at least one prior cancer treatment and the cancer had progressed subsequent to the prior treatment.

8. The method of claim 1 , wherein the pembrolizumab is administered to the patient intravenously.

9. The method of claim 4 , wherein the biological sample was tested by a method comprising immunohistochemistry testing, next generation sequencing or PCR testing.

10. The method of claim 1 , wherein the biological sample was tested by a method comprising assessing one or more markers selected from the group consisting of BAT-25, BAT-26, MONO-27, NR-21 and NR-24.

11. A method for reducing the risk of progression of colorectal cancer in a human patient, the method comprising:
in response to determining that the colorectal cancer is microsatellite instability high or DNA mismatch repair deficient, treating a human patient having colorectal cancer that is microsatellite instability high or DNA mismatch repair deficient with a therapeutically effective amount of pembrolizumab, wherein a biological sample from the patient had previously been tested to determine whether the colorectal cancer is microsatellite instability high or DNA mismatch repair deficient.

12. The method of claim 11 , wherein the biological sample is tumor tissue from the patient.

13. The method of claim 11 , wherein the biological sample is a body fluid from the patient.

14. The method of claim 11 , wherein the colorectal cancer is microsatellite instability high.

15. The method of claim 11 , wherein the colorectal cancer is DNA mismatch repair deficient.

16. The method of claim 11 , wherein the colorectal cancer is metastatic colorectal cancer.

17. The method of claim 11 , wherein the patient had received at least one prior cancer treatment and the cancer had progressed subsequent to the prior treatment.

18. The method of claim 11 , wherein the pembrolizumab is administered to the patient intravenously.

19. The method of claim 14 , wherein the biological sample was tested by a method comprising immunohistochemistry testing, next generation sequencing or PCR testing.

20. The method of claim 11 , wherein the biological sample was tested by a method comprising assessing one or more markers selected from the group consisting of BAT-25, BAT-26, MONO-27, NR-21 and NR-24.

21. The method of claim 1 , wherein the treatment increases the median progression free survival of patients having colorectal cancer that is microsatellite instability high or DNA mismatch repair deficient compared to the median progression free survival of patients having colorectal cancer that is not microsatellite instability high or DNA mismatch repair deficient.

22. The method of claim 1 , wherein the treatment increases the median overall survival of patients having colorectal cancer that is microsatellite instability high or DNA mismatch repair deficient compared to the median overall survival of patients having colorectal cancer that is not microsatellite instability high or DNA mismatch repair deficient.

23. The method of claim 11 wherein the treatment increases the median progression free survival of patients having colorectal cancer that is microsatellite instability high or DNA mismatch repair deficient compared to the median progression free survival of patients having colorectal cancer that is not microsatellite instability high or DNA mismatch repair deficient.

24. The method of claim 11 , wherein the treatment increases the median overall survival of patients having colorectal cancer that is microsatellite instability high or DNA mismatch repair deficient compared to the median overall survival of patients having colorectal cancer that is not microsatellite instability high or DNA mismatch repair deficient.

25. The method of claim 1 , wherein the method results in an objective response rate of 40% or higher for microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients.

26. The method of claim 25 , wherein the microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients have received a prior cancer therapy drug and the cancer had progressed following the prior cancer therapy.

27. The method of claim 1 , wherein the method results in a probability of progression-free survival at 20 weeks for microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients is at least 78%.

28. The method of claim 27 , wherein the microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients have received a prior cancer therapy drug and the cancer had progressed following the prior cancer therapy.

29. The method of claim 1 , wherein the method results in a probability of progression-free survival at 9 months for microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients is at least 60%.

30. The method of claim 29 , wherein the microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients have received a prior cancer therapy drug and the cancer had progressed following the prior cancer therapy.

31. The method of claim 6 , wherein the method results in an objective response rate of 40% or higher for microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients.

32. The method of claim 31 , wherein the microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients have received a prior cancer therapy drug and the cancer had progressed following the prior cancer therapy.

33. The method of claim 6 , wherein the method results in a probability of progression-free survival at 20 weeks for microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients is at least 78%.

34. The method of claim 33 , wherein the microsatellite instability high or DNA mismatch repair deficient colorectal cancer patients have received a prior cancer therapy drug and the cancer had progressed following the prior cancer therapy.

35. The method of claim 6 , wherein the method results in a probability of progression-free survival at 9 months for microsatellite instability high or DNA mismatch rep

Assignees

• Univ Johns Hopkins

Inventors

• Diaz Luis
• Vogelstein Bert
• Kinzler Kenneth W
• Papadopoulos Nickolas
• Le Dung
• Pardoll Drew M
• Topalian Suzanne L

Classifications

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/2803 Primary

  against the immunoglobulin superfamily · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title